Vivoryon Therapeutics N.V. to Participate in Upcoming Conferences
Vivoryon Therapeutics N.V. to Participatein Upcoming Conferences
Halle (Saale) / Munich, Germany, June1, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company focused on the discovery and development of small molecule medicines to modulate the activity and stability of pathologically altered proteins, today announced that the Company’s management will participate in the following conferences:
BIO International Convention (June 5-8, 2023)
Only one-on-one meetings
Venue: Boston Convention & Exhibition Center; Boston, USA
Jefferies Healthcare Conference (June7-9, 2023)
Date: June 7, 2023
Presentation Time: 08:00 am EDT in Track 4
Venue: Marriott Marquis; New York City, USA
A webcast of the presentation will be available via the "Presentations & Webcasts" page in the Investor Relations section on the Company's website at www.vivoryon.com and will be archived on the Company's website for 90 days following the conference.
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation, we strive to change the lives of patients in need suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings. Beyond our lead program, varoglutamstat, which is in Phase 2 clinical development to treat Alzheimer’s disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis. www.vivoryon.com
Vivoryon Forward Looking Statements
This press release includes forward-looking statements, including, without limitation, those regarding the business strategy, management plans and objectives for future operations of the Vivoryon Therapeutics N.V. (the “Company”), estimates and projections with respect to the market for the Company’s products and forecasts and statements as to when the Company’s products may be available. Words such as “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “project,” “predict,” “should” and “will” and similar expressions as they relate to the Company are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance; rather they are based on the Management’s current expectations and assumptions about future events and trends, the economy and other future conditions. The forward-looking statements involve a number of known and unknown risks and uncertainties. These risks and uncertainties and other factors could materially adversely affect the outcome and financial effects of the plans and events described herein. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements and from expectations. As a result, no undue reliance should be placed on such forward-looking statements. This press release does not contain risk factors. Certain risk factors that may affect the Company’s future financial results are discussed in the published annual financial statements of the Company. This press release, including any forward-looking statements, speaks only as of the date of this press release. The Company does not assume any obligation to update any information or forward-looking statements contained herein, save for any information required to be disclosed by law.
For more information, please contact:
Investor Contact
Stern IR
Julie Seidel
Tel: +1 212-698-8684
Email: SternIR-Vivoryon@sternir.com
Media Contact
Trophic Communications
Valeria Fisher
Tel: +49 175 8041816
Email: vivoryon@trophic.eu
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
SKEL fjárfestingafélag hf.: Buy-back programme week 3825.9.2023 12:13:10 CEST | Press release
In week 38 2023, SKEL fjárfestingafélag hf. purchased in total 8,100,000 own shares for total amount of 103,255,000 ISK as follows: DateTimePurchased sharesPricePurchase priceTotal own shares18.9.202310:151,500,00012.10018,150,00020,018,51819.9.202309:431,600,00012.40019,840,00021,618,51820.9.202309:381,000,00013.10013,100,00022,618,51820.9.202312:05750,00013.1009,825,00023,368,51821.9.202310:051,000,00012.80012,800,00024,368,51821.9.202315:01800,00013.00010,400,00025,168,51822.9.202309:35500,00013.2006,600,00025,668,51822.9.202309:35500,00013.2006,600,00026,168,51822.9.202311:02450,00013.2005,940,00026,618,5188,100,000103.255.00026.618.518 The execution of the buy-back programme is in accordance with Chapter VIII of the Company Act No 2/1995, Article 5 of the Regulation of the European parliament and of the Council (EU) on Market Fraud No. 60/2021, the Commissions Delegated Regulation No. 2016/1052 and the Act on Actions against Market Fraud No. 60/2021. Before the purchase SKEL held
Standard Lithium Strengthens C-Suite: Salah Gamoudi Appointed CFO, Kara Norman Steps Into New Role as CAO25.9.2023 12:01:09 CEST | Press release
VANCOUVER, British Columbia, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV:SLI) (NYSE American:SLI) (FRA:S5L), a leading near-commercial lithium company, today announced an enhanced C-suite with the addition of Salah Gamoudi as Chief Financial Officer, effective October 1, 2023. This decision aligns with the Company's efforts to bolster its senior leadership as it prepares for a dynamic phase of growth. Robert Mintak, CEO and Director of Standard Lithium, stated, “As we place greater emphasis on commercial construction, resource expansion, and strategic partnerships, Salah's addition is timely. Kara Norman's leadership as CFO, especially during our early growth and the NYSE American listing, has been foundational. With Salah joining as CFO and Kara transitioning to the Chief Accounting Officer role, we're strategically positioning our leadership for the Company's next chapter.” Salah Gamoudi commented, “Joining Standard Lithium at
Concentrix and Webhelp Complete Combination, Creating a Diversified Global CX Leader, Well-Positioned for Growth25.9.2023 12:00:00 CEST | Press release
NEWARK, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Concentrix Corporation (NASDAQ: CNXC), a leading global provider of customer experience (CX) services and technologies, today announced it has closed its combination with Webhelp and the integration of the two companies is underway. While the combined company finalizes its permanent name, it will operate under the trade name Concentrix + Webhelp. This combination further positions Concentrix + Webhelp as a global CX leader, with an expanded breadth of generative AI solutions, digital capabilities, and high-value services. It also strengthens its end-to-end CX value proposition, with one of the most robust, well-balanced global footprints in the industry to help the world’s best brands transform customer experiences and achieve their business goals. “I am excited to embark on this new journey together and believe that, with our combined strengths, we are uniquely positioned to redefine the industry and design, build and run the future o
eGain Launches AssistGPT™, First-of-Its-Kind Solution to Automate Knowledge for Customer Engagement25.9.2023 12:00:00 CEST | Press release
SUNNYVALE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- eGain Corporation (NASDAQ: EGAN), the leading knowledge management platform provider for customer engagement automation, launched eGain AssistGPT™ at its Solve™ 23 conference, being held on September 25, at the Brewery, London. An integral part of the eGain Knowledge Hub and powered by Generative AI out of the box, AssistGPT is a comprehensive zero-code solution for Knowledge Automation. For example, knowledge content draft creation, which used to take weeks, can now be completed in just a few minutes. The solution also helps customers in their omnichannel journeys with quick answers and contact center agents and business analysts in the flow of their work. An AI Console allows administrators to define guard rails for the use of generative AI, manage prompts, and orchestrate it with other AI technologies in the enterprise. AssistGPT comes with a best practice prompt library, which enables organizations to add business-specific promp
EPKINLYTM (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare as the First Bispecific Antibody to Treat Adults Patients with Certain Types of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)25.9.2023 11:55:00 CEST | Press release
Media Release Subcutaneous EPKINLYTM(epcoritamab) is the first and only bispecific antibody approved in Japan to treat adult patients with certain types of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapyApproval based on results of EPCORETM NHL-3 and EPCORETM NHL-1 clinical trials, evaluating EPKINLYin patients with certain types of R/RLBCLLBCLis a common form of non-Hodgkin’s lymphoma (NHL) and currently has limited treatment options, particularly in the R/R setting COPENHAGEN, Denmark; September 25, 2023 – Genmab A/S (Nasdaq:GMAB) announcedtoday that the Japan Ministry of Health, Labour and Welfare has approved EPKINLYTM (epcoritamab) as the first and only T-cell engaging bispecific antibody treatment in Japan of adult patients with certain types of relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL)